Related Experiment Video
Updated: Dec 14, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Severe infusion reaction due to nivolumab: A case report
Seema Kumari1,2, James Yun3,4, James R Soares5
1Medical Oncology Department, Nepean Hospital Cancer Care Centre, Kingswood, New South Wales, Australia.
Background:
Nivolumab is an anti-PD1 immune checkpoint inhibitor commonly used for the treatment of solid organ and hematological malignancies. Severe infusion reaction due to nivolumab is quite rare.
Case:
We report a case of severe infusion reaction due to nivolumab necessitating ICU admission and withdrawal of further nivolumab use in a patient with metastatic non-small cell lung cancer.
Conclusion:
Our knowledge and expertise with the use of immune checkpoint inhibitors are still evolving. This report highlights one of the rare possible side-effects that clinicians and patients may have to face with increasing indications and use of nivolumab in day to day practice.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Allergic Drug Reactions
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
Myocarditis IV: Nursing Management
Drug Accumulation During Multiple Dosing: Repetitive IV Injections